DTI Drug Target Insights 2023; 17: 54-57ISSN 1177-3928 | DOI: 10.33393/dti.2023.2573ORIGINAL RESEARCH ARTICLE Drug Target Insights - ISSN 1177-3928 - www.aboutscience.eu/dti © 2023 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Commercial use is not permitted and is subject to Publisher’s permissions. Full information is available at www.aboutscience.eu Are calcium channel blockers related to lung cancer? Ratchanon Rattanathanoo, Jarin Chindaprasirt, Watchara Boonsawat, Panita Limpawattana, Sittichai Khamsai, Kittisak Sawanyawisuth Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen - Thailand ABSTRACT Background: Calcium channel blocker (CCB) is a common antihypertensive agent for the treatment of hyperten- sion. There are inconsistent data of an association of CCB and lung cancer in the literature. This study aimed to evaluate this association by a case-control design. Methods: The inclusion criteria were adult patients 18 years or over, diagnosed with hypertension, lung cancer or pulmonary tuberculosis, and presenting with one of the suggestive symptoms of lung cancer. Those who were pregnant or had a diagnosis of lung cancer or pulmonary tuberculosis prior to the diagnosis of hypertension were excluded. Diagnosis of lung cancer was made pathologically, while tuberculosis was made by positive acid-fast bacilli on sputum examination, sputum culture positive for Mycobacterium tuberculosis, or polymerase chain reaction positive for M. tuberculosis with a chest x-ray compatible with tuberculosis. Cases were those diagnosed with lung cancer, while controls were those diagnosed with tuberculosis. Factors associated with lung cancer were calculated by logistic regression analysis. Results: There were 178 patients who met the study criteria. Of those, 69 patients (38.8%) were in the case group. The lung cancer group had EGFR gene mutation in 21 patients (52.5%) and adenocarcinoma was the most common cell type of lung cancer (55 patients; 79.7%). There were two factors independently associated with lung cancer including dyslipidemia and family history of lung cancer. Conclusions: CCB was not associated with lung cancer in patients with hypertension but dyslipidemia and family history of lung cancer were independently associated with lung cancer in this setting. Keywords: Dyslipidemia, Family history, Risk factors Received: February 7, 2023 Accepted: May 1, 2023 Published online: May 19, 2023 Corresponding author: Sittichai Khamsai Department of Medicine, Khon Kaen University Khon Kaen 40002 - Thailand sittikh@kku.ac.th Kittisak Sawanyawisuth 123 Mitraparp Road, Department of Medicine Faculty of Medicine, Khon Kaen University Khon Kaen, 40002 - Thailand kittisak@kku.ac.th in reduction of stroke by up to 40%, and reduction in heart failure by up to 50% (3). Additionally, treatment of conditions or comorbid diseases of hypertension is also crucial (4-8). Antihypertensive agents are effective in blood pressure lowering including calcium channel blockers (CCBs). Even though CCB is recommended as the first-line treatment for hypertension (9), it has been reported to be increasing the risk of cancer (10). Several studies including a meta-analy- sis showed that CCB was associated with lung cancer with adjusted odds ratio of 1.13 (95% confidence interval 1.06, 1.21) (11-13), while other studies did not find this association (14,15). As there are inconsistent and inconclusive data on this issue, this study aimed to evaluate the additional asso- ciation of CCB and lung cancer. Methods This was a case-control study conducted at Srinagarind Hospital, Khon Kaen University, Thailand. The inclusion cri- teria were adult patients 18 years or over, diagnosed with lung cancer or pulmonary tuberculosis, and presenting with one of the following symptoms: hemoptysis, chronic cough, constitutional symptoms, lung mass, and a checkup. Those who were pregnant or with diagnosis of lung cancer Introduction Hypertension is a common disease, with an estimated 1.39 billion adults diagnosed with hypertension (1). Generally, the prevalence of hypertension was 31.1% worldwide in 2010. The main goal of hypertension treatment is to achieve blood pres- sure control. A previous report found that only 23% of women and 18% of men with hypertension had a good blood pres- sure control globally (2). Blood pressure lowering may result https://doi.org/10.33393/dti.2023.2573 https://creativecommons.org/licenses/by-nc/4.0/legalcode Rattanathanoo et al Drug Target Insights 2023; 17: 55 © 2023 The Authors. Published by AboutScience - www.aboutscience.eu or pulmonary tuberculosis prior to the diagnosis of hyper- tension were excluded. Diagnosis of lung cancer was made pathologically, while tuberculosis was made by positive acid- fast bacilli on sputum examination, sputum culture positive for Mycobacterium tuberculosis, or polymerase chain reac- tion (PCR) positive for M. tuberculosis with a chest x-ray compatible with tuberculosis. Cases were those diagnosed with lung cancer, while controls were those diagnosed with tuberculosis. The study period was between 2007 and 2019. Eligible patients were recorded for baseline characteris- tics, medications, and risk factors for lung cancer. Baseline characteristics included age, sex, body mass index, comor- bid diseases, alcohol consumption, and smoking history. Risk factors of lung cancer were also recorded: family history of lung cancer, occupational exposure, or chest wall radia- tion. Antihypertensive medications particularly CCB were retrieved as well as duration of CCB use. The primary out- come of this study was to evaluate the association of lung cancer and CCB. Sample size calculation Based on a probability of event in the case and control group of 0.6 and 0.3, the required sample size for case group was 49 patients with a confidence of 95% and power of 80%. The control group was enrolled for a ratio of case:control of 1:1-2. Statistical analyses Patients were categorized into two groups: lung cancer (cases) and tuberculosis (controls). Descriptive statistics were used to compare differences between both groups: indepen- dent t-test or Wilcoxon rank sum test for numerical variables and chi-square or Fisher’s exact test for categorical variables. Factors associated with lung cancer were calculated by logis- tic regression analysis. Multicollinearity was checked in the logistic regression analysis. The final model was executed for goodness of fit by Hosmer-Lemeshow test. Statistical analy- ses were calculated by STATA software version 10.1 (College Station, Texas, USA). Results There were 178 patients who met the study criteria. Of those, 69 patients (38.8%) were in the case group or lung cancer group. The lung cancer group had tested for gene mutation in 40 patients (56.0%). EGFR was the most common gene mutation (21 patients; 52.5%), followed by no mutation (15 patients; 37.5%), and ALK mutation (4 patients; 10%). Adenocarcinoma was the most common cell type of lung cancer (55 patients; 79.7%), followed by squamous cell carci- noma (8 patients; 11.6%). Table I shows baseline characteris- tics and CCB treatment of the case and control groups. There were three significant factors between both groups, namely dyslipidemia, obstructive sleep apnea, and family history of lung cancer. The case group had significantly higher propor- tions of these three factors than the control group such as family history of lung cancer (15.9% vs. 0.9%; p < 0.001). TABLE I - Baseline characteristics and CCB treatment of patients with hypertension categorized by lung cancer (case group) and tuberculosis (control group) Factors Cases (n = 69) Controls (n = 109) p value Age, years* 67 (61,71) 66 (59,71) 0.603 Male 44 (63.8) 77 (70.6) 0.338 Female 25 (36.2) 32 (29.4) BMI 0.676  <19 13 (18.8) 17 (15.9)  19-24.5 16 (23.2) 25 (23.4)  24.5-30 5 (7.2) 4 (3.7)  >30 35 (50.7) 61 (57.0) Smoking 40 (58) 64 (58.7) 0.922 Alcohol drinking 28 (40.6) 53 (48.6) 0.294 Comorbidities  CVD 10 (14.5) 17(15.6) 0.841  Dyslipidemia 29 (42) 27 (24.8) 0.016  DM 27 (39.1) 48 (44) 0.518  OSA 5 (7.2) 1 (0.9) 0.033  CKD 10 (14.5) 23 (21.1) 0.269  Ischemic stroke 6 (8.7) 2 (1.8) 0.057  Autoimmune 2 (2.9) 4 (3.7) >0.999  HBV infection 2 (2.9) 3 (2.8) >0.999  HCV infection 0 5 (4.6) 0.158  Hyperthyroidism 1 (1.4) 0 0.388 Family history of lung cancer 11 (15.9) 1 (0.9) <0.001 Occupational exposure 1 (1.4) 2 (1.8) >0.999 Chest wall radiation 0 0 NA CCB used 45 (65.2) 62 (56.9) 0.268 CCB duration, years* 5 (3-10) 6 (2.8-8.2) 0.642 Data presented as number (percentage) except * indicated as median (1st-3rd quartile range). BMI = body mass index; CCB = calcium channel blocker; CKD = chronic kidney disease; CVD = cardiovascular disease; DM = diabetic mellitus; HBV = hepatitis B virus; HCV = hepatitis C virus; NA = not available; OSA = obstructive sleep apnea. There were five factors in the final model for prediction of lung cancer (Tab. II). Two factors were independently associ- ated with lung cancer including dyslipidemia and family his- tory of lung cancer. These factors had an adjusted odds ratio (95% confidence interval) of 2.12 (1.07, 4.23) and 22.43 (2.76, 182.36), respectively. The Hosmer-Lemeshow chi-square was 4.88 (p = 0.559). CCB use had an adjusted odds ratio of 1.50 (95% confidence interval of 0.53, 2.01). Discussion This study found that CCB was not associated with lung cancer but dyslipidemia and family history of lung cancer did. CCB and lung cancer56 © 2023 The Authors. Drug Target Insights - ISSN 1177-3928 - www.aboutscience.eu/dti CCB-related cancer is still inconclusive and needs further studies to evaluate this issue (16). The possible mechanisms of CCB-related cancer include cell growth, cell proliferation, and cell apoptosis (17,18). However, some studies found that CCB may reduce risks of lung cancer as CCB may sup- press lung tumorigenesis and suppression of CACNA2D2, a link to non–small cell lung cancer (19,20). Previous studies and meta-analyses that reported on the risk of CCB on lung cancer were mainly from database study with asymptomatic controls, while this study evaluated this association with a case-control study using controls who presented with similar symptoms of lung cancer. Rotshild et al published one meta-analysis and one nested case-control study. Both studies reported that CCB was asso- ciated with lung cancer with an adjusted odds ratio of 1.13 (95% confidence interval 1.06, 1.21) and a risk ratio of 1.15 (95% confidence interval 1.01-1.30) (12,13). However, there are some limitations in both studies. The case-control study did not state how lung cancer diagnosis was made and sig- nificant factors in this study, namely dyslipidemia and family history of lung cancer, were not studied (12). The results of this study were compatible with the large population cohort study in Hong Kong (21). Among 84,116 patients with lung cancer, CCB did not increase the risk of lung cancer regardless of aspirin therapy. The hazard ratios for both settings were 0.89 (95% confidence interval of 0.73, 1.08) for CCB and 0.82 (95% confidence interval of 0.64, 1.06) for CCB plus aspirin. As data regarding CCB and lung cancer are still conflicting, further studies are required. This study found that dyslipidemia was associated with lung cancer, which was supported by a previous study from China (22). High-density lipoprotein cholesterol (HDL- C) reduced the risk of non–small cell lung cancer by 77% (adjusted odds ratio of 0.233; 95% confidence interval of 0.134, 0.407). There are several biological explanations for the reduction of cancer and high HDL-C, such as suppres- sion of signaling via lipid raft formation and reduction of viability and proliferation (23,24). Regarding family history of lung cancer, several studies support this finding conducted in twins, women, and nonsmokers (25-27). This association may be explained by second-hand smokers or genetic factors such as HER2 gene or EGFR variant (28-32). Study Limitations There are some limitations in this study. First, this was a study conducted in a single, referral university hospital result- ing in a small sample size. Second, some factors were not completely evaluated such as genetic factors, sleep apnea, or aspirin therapy (21,33-38). Similar to previous published articles, smoking history may be underestimated as smoking status may not be recorded in the medical records (12,13,21). Additionally, selection bias may have existed as this study enrolled only those with pathological diagnosis of lung can- cer. This may also result in small sample size. Finally, some factors such as alcohol consumption may not be studied or may be missing due to retrospective design. Conclusions CCB was not associated with lung cancer in patients with hypertension but dyslipidemia and family history of lung cancer were independently associated with lung cancer in this setting. Disclosures Conflict of interest: The authors declare that they have no conflicts of interest. Financial support: This study was funded by a grant from Khon Kaen University, Faculty of Medicine, Thailand (Grant Number: MN66003). References 1. Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223-237. CrossRef PubMed 2. Zhou B, Carrillo-Larco RM, Danaei G, et al; NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304): 957-980. CrossRef PubMed 3. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560- 2572. CrossRef PubMed 4. Khamsai S, Mahawarakorn P, Limpawattana P, et al. Prevalence and factors correlated with hypertension secondary from obstructive sleep apnea. Multidiscip Respir Med. 2021;16(1): 777. CrossRef PubMed 5. Jeerasuwannakul B, Sawunyavisuth B, Khamsai S, Sawanyawisuth K. Prevalence and risk factors of proteinuria in patients with type 2 diabetes mellitus. Asia Pac J Sci Technol. 2021;26(04):APST-26- 04-02: 1-5. CrossRef 6. Manasirisuk P, Chainirun N, Tiamkao S, et al. Efficacy of generic atorvastatin in a real-world setting. Clin Pharmacol. 2021;13:45-51. CrossRef PubMed 7. Soontornrungsun B, Khamsai S, Sawunyavisuth B, et al. Obstruc- tive sleep apnea in patients with diabetes less than 40 years of TABLE II - Factors associated with lung cancer in patients with hy- pertension by logistic regression analysis Factors Unadjusted OR 95% CI Adjusted OR 95% CI Smoking 0.97 0.53, 1.79 1.03 0.53, 2.01 Dyslipidemia 2.20 1.15, 4.20 2.12 1.07, 4.23 Obstructive sleep apnea 8.44 0.96, 73.84 7.50 0.79, 71.17 Family history of lung cancer 20.48 2.58, 162.61 22.43 2.76, 182.36 Calcium channel blocker used 1.42 0.76, 2.67 1.50 0.53, 2.01 CI = confidence interval; OR = odds ratio. https://doi.org/10.1038/s41581-019-0244-2 https://www.ncbi.nlm.nih.gov/pubmed/32024986 https://doi.org/10.1016/S0140-6736(21)01330-1 https://www.ncbi.nlm.nih.gov/pubmed/34450083 https://doi.org/10.1001/jama.289.19.2560 https://www.ncbi.nlm.nih.gov/pubmed/12748199 https://doi.org/10.4081/mrm.2021.777 https://www.ncbi.nlm.nih.gov/pubmed/34650797 https://doi.org/10.14456/apst.2021.32 https://doi.org/10.2147/CPAA.S285750 https://www.ncbi.nlm.nih.gov/pubmed/33707972 Rattanathanoo et al Drug Target Insights 2023; 17: 57 © 2023 The Authors. Published by AboutScience - www.aboutscience.eu age. Diabetes Metab Syndr. 2020;14(6):1859-1863. CrossRef PubMed 8. Khamsai S, Chootrakool A, Limpawattana P, et al. Hypertensive crisis in patients with obstructive sleep apnea-induced hyperten- sion. BMC Cardiovasc Disord. 2021;21(1):310. CrossRef PubMed 9. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520. CrossRef PubMed 10. Pahor M, Guralnik JM, Salive ME, Corti MC, Carbonin P, Havlik RJ. Do calcium channel blockers increase the risk of cancer? Am J Hypertens. 1996;9(7):695-699. CrossRef PubMed 11. Azoulay L, Assimes TL, Yin H, Bartels DB, Schiffrin EL, Suissa S. Long-term use of angiotensin receptor blockers and the risk of cancer. PLoS One. 2012;7(12):e50893. CrossRef PubMed 12. Rotshild V, Azoulay L, Feldhamer I, et al. Calcium channel block- ers and the risk for lung cancer: a population-based nested case-control study. Ann Pharmacother. 2019;53(5):445-452. CrossRef PubMed 13. Rotshild V, Azoulay L, Zarifeh M, et al. The risk for lung cancer incidence with calcium channel blockers: a systematic review and meta-analysis of observational studies. Drug Saf. 2018;41(6):555- 564. CrossRef PubMed 14. Hole DJ, Gillis CR, McCallum IR, et al. Cancer risk of hyperten- sive patients taking calcium antagonists. J Hypertens. 1998; 16(1):119-124. CrossRef PubMed 15. Michels KB, Rosner BA, Walker AM, et al. Calcium channel blockers, cancer incidence, and cancer mortality in a cohort of U.S. women: the nurses’ health study. Cancer. 1998;83(9):2003- 2007. CrossRef PubMed 16. Yang R, Zhang Y, Liao X, Yao Y, Huang C, Liu L. The relation- ship between anti-hypertensive drugs and cancer: anxiety to be resolved in urgent. Front Pharmacol. 2020;11:610157. CrossRef PubMed 17. Mason RP. Calcium channel blockers, apoptosis and cancer: is there a biologic relationship? J Am Coll Cardiol. 1999;34(7): 1857-1866. CrossRef PubMed 18. Jick H, Jick S, Derby LE, Vasilakis C, Myers MW, Meier CR. Calcium- channel blockers and risk of cancer. Lancet. 1997;349(9051): 525-528. CrossRef PubMed 19. Boo H-J, Min H-Y, Jang H-J, et al. The tobacco-specific carcin- ogen-operated calcium channel promotes lung tumorigen- esis via IGF2 exocytosis in lung epithelial cells. Nat Commun. 2016;7(1):12961. CrossRef PubMed 20. Carboni GL, Gao B, Nishizaki M, et al. CACNA2D2-mediated apop- tosis in NSCLC cells is associated with alterations of the intracel- lular calcium signaling and disruption of mitochondria membrane integrity. Oncogene. 2003;22(4):615-626. CrossRef PubMed 21. Li J, Lam ASM, Yau STY, Yiu KKL, Tsoi KKF. Antihypertensive treatments and risks of lung cancer: a large population-based cohort study in Hong Kong. BMC Cancer. 2021;21(1):1202. CrossRef PubMed 22. Hao B, Yu M, Sang C, Bi B, Chen J. Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study. Lipids Health Dis. 2018;17(1):278. CrossRef PubMed 23. Su F, Grijalva V, Navab K, et al. HDL mimetics inhibit tumor devel- opment in both induced and spontaneous mouse models of colon cancer. Mol Cancer Ther. 2012;11(6):1311-1319. CrossRef PubMed 24. Wolfe AR, Atkinson RL, Reddy JP, et al. High-density and very- low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflamma- tory breast cancer. Int J Radiat Oncol Biol Phys. 2015;91(5):1072- 1080. CrossRef PubMed 25. Lissowska J, Foretova L, Dabek J, et al. Family history and lung cancer risk: international multicentre case-control study in Eastern and Central Europe and meta-analyses. Cancer Causes Control. 2010;21(7):1091-1104. CrossRef PubMed 26. Yin X, Chan CPY, Seow A, Yau W-P, Seow WJ. Association between family history and lung cancer risk among Chinese women in Singapore. Sci Rep. 2021;11(1):21862. CrossRef PubMed 27. Kanwal M, Ding X-J, Cao Y. Familial risk for lung cancer. Oncol Lett. 2017;13(2):535-542. CrossRef PubMed 28. Scragg R, Glover M. Parental and adolescent smoking: does the association vary with gender and ethnicity? N Z Med J. 2007;120(1267):U2862. PubMed 29. Salber EJ, MacMahon B. Cigarette smoking among high school students related to social class and parental smoking habits. Am J Public Health Nations Health. 1961;51(12):1780-1789. CrossRef PubMed 30. Coté ML, Liu M, Bonassi S, et al. Increased risk of lung can- cer in individuals with a family history of the disease: a pooled analysis from the International Lung Cancer Consortium. Eur J Cancer. 2012;48(13):1957-1968. CrossRef PubMed 31. Yamamoto H, Higasa K, Sakaguchi M, et al. Novel germline mutation in the transmembrane domain of HER2 in familial lung adenocarcinomas. J Natl Cancer Inst. 2014;106(1):djt338. CrossRef PubMed 32. Bell DW, Gore I, Okimoto RA, et al. Inherited susceptibility to lung cancer may be associated with the T790M drug resis- tance mutation in EGFR. Nat Genet. 2005;37(12):1315-1316. CrossRef PubMed 33. Sawunyavisuth B, Ngamjarus C, Sawanyawisuth K. A meta- analysis to identify factors associated with CPAP machine pur- chasing in patients with obstructive sleep apnea. Biomed Rep. 2022;16(6):45. CrossRef PubMed 34. Sanlung T, Sawanyawisuth K, Silaruks S, et al. Clinical char- acteristics and complications of obstructive sleep apnea in Srinagarind hospital. J Med Assoc Thai. 2020;103(1):36-39. 35. Khamsai S, Kachenchart S, Sawunyavisuth B, et al. Prevalence and risk factors of obstructive sleep apnea in hypertensive emer- gency. J Emerg Trauma Shock. 2021;14(2):104-107. CrossRef PubMed 36. Sawunyavisuth B, Ngamjarus C, Sawanyawisuth K. Any effec- tive intervention to improve CPAP adherence in children with obstructive sleep apnea: a systematic review. Glob Pediatr Health. 2021;8:1-8. CrossRef 37. Sawunyavisuth B. What personal experiences of CPAP use affect CPAP adherence and duration of CPAP use in OSA patients? J Med Assoc Thai. 2018;101(7):S245-S249. 38. Kaewkes C, Sawanyawisuth K, Sawunyavisuth B. Are symptoms of obstructive sleep apnoea related to good continuous positive airway pressure compliance? ERJ Open Res. 2020;6(3):00169- 02019. CrossRef PubMed https://doi.org/10.1016/j.dsx.2020.09.008 https://www.ncbi.nlm.nih.gov/pubmed/32992217 https://doi.org/10.1186/s12872-021-02119-x https://www.ncbi.nlm.nih.gov/pubmed/34162333 https://doi.org/10.1001/jama.2013.284427 https://www.ncbi.nlm.nih.gov/pubmed/24352797 https://doi.org/10.1016/0895-7061(96)00186-0 https://www.ncbi.nlm.nih.gov/pubmed/8806983 https://doi.org/10.1371/journal.pone.0050893 https://www.ncbi.nlm.nih.gov/pubmed/23251399 https://doi.org/10.1177/1060028018814684 https://www.ncbi.nlm.nih.gov/pubmed/30442036 https://doi.org/10.1007/s40264-018-0644-4 https://www.ncbi.nlm.nih.gov/pubmed/29484611 https://doi.org/10.1097/00004872-199816010-00017 https://www.ncbi.nlm.nih.gov/pubmed/9533425 https://doi.org/10.1002/(SICI)1097-0142(19981101)83:9<2003::AID-CNCR17>3.0.CO;2-3 https://www.ncbi.nlm.nih.gov/pubmed/9806660 https://doi.org/10.3389/fphar.2020.610157 https://www.ncbi.nlm.nih.gov/pubmed/33381045 https://doi.org/10.1016/S0735-1097(99)00447-7 https://www.ncbi.nlm.nih.gov/pubmed/10588195 https://doi.org/10.1016/S0140-6736(97)80084-0 https://www.ncbi.nlm.nih.gov/pubmed/9048789 https://doi.org/10.1038/ncomms12961 https://www.ncbi.nlm.nih.gov/pubmed/27666821 https://doi.org/10.1038/sj.onc.1206134 https://www.ncbi.nlm.nih.gov/pubmed/12555074 https://doi.org/10.1186/s12885-021-08971-6 https://www.ncbi.nlm.nih.gov/pubmed/34763668 https://doi.org/10.1186/s12944-018-0925-z https://www.ncbi.nlm.nih.gov/pubmed/30522496 https://doi.org/10.1158/1535-7163.MCT-11-0905 https://www.ncbi.nlm.nih.gov/pubmed/22416044 https://doi.org/10.1016/j.ijrobp.2014.12.039 https://www.ncbi.nlm.nih.gov/pubmed/25832697 https://doi.org/10.1007/s10552-010-9537-2 https://www.ncbi.nlm.nih.gov/pubmed/20306329 https://doi.org/10.1038/s41598-021-00929-9 https://www.ncbi.nlm.nih.gov/pubmed/34750403 https://doi.org/10.3892/ol.2016.5518 https://www.ncbi.nlm.nih.gov/pubmed/28356926 https://www.ncbi.nlm.nih.gov/pubmed/18157188 https://doi.org/10.2105/AJPH.51.12.1780 https://www.ncbi.nlm.nih.gov/pubmed/14496305 https://doi.org/10.1016/j.ejca.2012.01.038 https://www.ncbi.nlm.nih.gov/pubmed/22436981 https://doi.org/10.1093/jnci/djt338 https://www.ncbi.nlm.nih.gov/pubmed/24317180 https://doi.org/10.1038/ng1671 https://www.ncbi.nlm.nih.gov/pubmed/16258541 https://doi.org/10.3892/br.2022.1528 https://www.ncbi.nlm.nih.gov/pubmed/35620316 https://doi.org/10.4103/JETS.JETS_47_20 https://www.ncbi.nlm.nih.gov/pubmed/34321809 https://doi.org/10.1177/2333794X211019884 https://doi.org/10.1183/23120541.00169-2019 https://www.ncbi.nlm.nih.gov/pubmed/33015148